Teva (TEVA) announced that it has entered into a strategic collaboration with Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, Formycon’s biosimilar candidate to Eylea in Europe, excluding Italy, and in Israel. Under the terms of the agreement, Teva will lead the commercialization of FYB203 in the designated regions, to be marketed under the brand name Ahzantive, subject to regulatory approval. In return, Klinge will receive milestone payments and a portion from the product’s revenue.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva, Samsung Bioepis enter partnership for commercialization of EPYSQLI
- Drugmakers Raise the Prices on 583 Products to Start 2025
- Catalyst settlement with Teva a positive event, says BofA
- Catalyst Pharmaceuticals up 18% after resumption following Teva settlement
- Catalyst Pharmaceuticals reports settlement of Firdapse patent litigation with Teva